Loading stock data…
$33.14+1.46 (+4.61%)
First Tracks Biotherapeutics, Inc.
| Metric (USD) | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — |
| Operating Income | -$34.94M↑ | -$52.81M↓ | -$45.90M↑ | -$51.28M |
| Net Income | -$33.37M↑ | -$50.48M↓ | -$42.45M↑ | -$47.20M |
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist th...